Effective Strategies for Treating and Managing Ocular Surface Health and Lid Margin Disease (In-Person CE Symposium)

Indianapolis, IN US
November 7, 2024

To register for the symposium, please click Register/Take Course.

Thursday, November 7, 2024
6:30 AM – 7:00 AM ET Registration and Breakfast
7:00 AM – 8:00 AM ET CE Symposium and Virtual Broadcast

Omni Severin Hotel

Fisher Ballroom – Mezzanine Level
40 West Jackson Place
Indianapolis, Indiana

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Review best practices in the diagnosis of blepharitis
  • Develop individualized treatment plans for patients with blepharitis
Course summary
Available credit: 
  • 1.00 COPE
Course opens: 
08/01/2024
Course expires: 
12/07/2024
Event starts: 
11/07/2024 - 7:00am EST
Event ends: 
11/07/2024 - 8:00am EST
Add to calendar: 
Omni Severin Hotel
40 West Jackson Place
Fisher Ballroom – Mezzanine Level
Indianapolis, IN 46225
United States
+1 (317) 634-6664
Omni Severin Hotel

Faculty

Marc Bloomenstein, OD, FAAO (Chair)
Director of Optometric Services
Schwartz Laser Eye Center
Scottsdale, Arizona

Mile Brujic, OD, FAAO
Partner
Premier Vision Group
Bowling Green, Ohio

Jaclyn Garlich, OD, FAAO
Owner
Envision Optometry
President
Glance by Eyes on Eyecare
Boston, Massachusetts

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

Faculty

Marc Bloomenstein, OD, is an advisory board member of AbbVie Inc, Alcon, Astellas Pharma Inc, Bausch & Lomb Incorporated, Bruder Healthcare, Harrow, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, Reichert, Inc, Sight Sciences, STAAR Surgical, Sun Pharmaceutical Industries, Inc, Sydnexis Inc, Tarsus Pharmaceuticals, Inc, Théa Pharma Inc, and Topcon Medical Systems, Inc; and is on the speakers bureau for AbbVie Inc, Bausch & Lomb Incorporated, Dompé US, Inc, Oyster Point Pharma, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, and Tarsus Pharmaceuticals, Inc.

Mile Brujic, OD, is a consultant for AbbVie Inc, Apellis Pharmaceuticals, Astellas Pharma Inc, Bausch & Lomb Incorporated, Dopavision, Glaukos Corporation, MDelite Laser & Aesthetic, Tarsus Pharmaceuticals, Inc, Viatris Inc, Visionix, Visus Therapeutics, and ZeaVision LLC; and is on the speakers bureau for Bausch & Lomb Incorporated, Nordic Pharma, Tarsus Pharmaceuticals, Inc, Viatris Inc, and ZeaVision LLC.

Jaclyn Garlich, OD, is a consultant for Lumenis, Ophthalmic Resources Partners, and Théa Pharma Inc; is an advisory board member of AbbVie Inc, Alcon, Aldeyra Therapeutics, Bausch & Lomb Incorporated, Bruder Healthcare, Novartis Pharmaceuticals Corporation, and Tarsus Pharmaceuticals, Inc; and is on the speakers bureau for AbbVie Inc, Bausch & Lomb Incorporated, Dompé US, Inc, and Tarsus Pharmaceuticals, Inc.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation Statement

COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 94023-TD (Synchronous In Person)
COPE Course Category: Treatment and Management of Ocular Disease

Administrator: 

This activity, COPE Activity Number XXXXXX, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus LLC has received commercial support from Tarsus Pharmaceuticals, Inc, and Théa Pharma Inc for this activity in the form of an unrestricted educational grant.

The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of  MedEdicus LLC, Tarsus Pharmaceuticals, Inc, or Théa Pharma Inc.

This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 328

Available Credit

  • 1.00 COPE
Please login or register to take this course.

To register for this symposium, please select the purple Take course button. You will receive an email confirmation. If you do not receive a confirmation, please check your spam folder or email info@mededicus.com.

We look forward to seeing you in Indianapolis on November 7!